Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Sleep and EEG biomarkers as avenues toward new treatment approaches in Angelman syndrome

Angelman syndrome (AS) is characterized by severe intellectual, speech and motor deficits [1]. The cause of AS is either disruption of the maternal ubiquitin-protein ligase E3A gene (UBE3A) (30%) or deletion of chromosome 15 at 15q11-q13 (70%). The deleted region includes UBE3A and GABRB3, GABRA5, and GABRG3, genes that encode the gamma-aminobutyric acid (GABA) type A receptor subunits β3, α5, and γ3. Several medical co-morbidities are associated with AS.

Sleep disturbance is a common medical co-morbidity, occurring in up to 80% of individuals with AS. Difficulty falling and staying asleep and reduced total sleep time are most common. The etiology of sleep disturbances in AS is multifactorial, involving genetic, co-morbid medical, and behavioral factors. Deletion of the GABRB3-GABRA5-GABRG3 gene grouping, which occurs in most cases of AS, probably contributes to the high prevalence of sleep problems and co-morbid epilepsy [2]. Epilepsy occurs in 80–90% of individuals with AS and can contribute to sleep problems. In a study of sleep disturbances and epilepsy in 290 subjects with AS, disturbed sleep was described by caregivers of 58% of the sample [3]. Among these subjects, 79% had epilepsy, and 69% of those with both sleep problems and epilepsy had multiple seizure types. Subjects with epilepsy non-responsive to more than two antiepileptic drugs (AEDs) had more significant sleep disturbances than those successfully treated with up to two AEDs. From a behavioral standpoint, urinary incontinence overnight may cause mid-nocturnal awakenings, and agitation in response to separation from preferred caregivers may play a role in the disturbed sleep.

Recent studies are attempting to identify biomarkers of the pathophysiology of sleep disturbances in AS using EEG. In a retrospective study, den Bakker and colleagues [4] identified two quantitative readouts of dysregulated sleep composition in children with AS: increased gamma coherence and fewer sleep spindles. Increased long-range gamma-band coherence during sleep and wakefulness suggests that, despite reduced structural connectivity, there may be fewer inhibitory constraints on efferent projections in the brain of individuals with AS. Sleep spindles, which are reduced in several neurodevelopmental disorders, are important for memory consolidation and learning. Another group tested the hypothesis that genes other than UBE3A located on 15q11-q13 cause differences in pathophysiology between AS genotypes [5]. In children and adolescents with AS, they found that an abnormality in the delta-band EEG indexes UBE3A-related pathophysiology, while theta- and beta-band EEG abnormalities index contributions from other genes, most likely the GABRB3-GABRA5-GABRG3 gene cluster.

Building upon the identification of biomarkers for disturbed sleep in AS, a Phase 2, 12-week randomized double-blind, placebo-controlled trial of gaboxadol (OV101), an extracellular delta-selective GABAA receptor agonist, was completed in 78 adults and adolescents [6]. At week 12, OV101 resulted in global improvement in significantly more subjects than did placebo. Sleep onset latency, overall sleep, and motor function were found to contribute to this global response.

Safe and potentially efficacious targeted therapies are being developed for interfering symptoms in AS. With continued progress, it is hoped that interventions will one day alter the course of this severe developmental disorder.

Funding and disclosure

This work was funded in part by the Angelman Syndrome Foundation and the Nancy Lurie Marks Family Foundation. CJM has no conflicts of interest to disclose. CJK has been compensated as a consultant, served on a scientific advisory board and received research support from Ovid Therapeutics, the sponsor of the trial of OV101 in AS.


  1. 1.

    Angelman H. ‘Puppet’ children a report on three cases. Dev Med Child Neurol. 1965;7:681–8.

    Article  Google Scholar 

  2. 2.

    DeLorey TM, Handforth A, Anagnostaras SG, Homanics GE, Minassian BA, Asatourian A, et al. Mice lacking the β3 subunit of the GABAA receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome. J Neurosci. 1998;18:8505–14.

    CAS  Article  Google Scholar 

  3. 3.

    Conant KD, Thibert RL, Thiele EA. Epilepsy and the sleep-wake patterns found in Angelman syndrome. Epilepsia. 2009;50:2497–500.

    Article  Google Scholar 

  4. 4.

    den Bakker H, Sidorov MS, Fan Z, Lee DJ, Bird LM, Chu CJ, et al. Abnormal coherence and sleep composition in children with Angelman syndrome: a retrospective EEG study. Mol Autism. 2018;9:32.

    Article  Google Scholar 

  5. 5.

    Frohlich J, Miller MT, Bird LM, Garces P, Purtell H, Hoener MC, et al. Electrophysiological phenotype in Angelman syndrome differs between genotypes. Biol Psychiatry. 2019;85:752–59.

    Article  Google Scholar 

  6. 6.

    Bird L, Ochoa-Lubinoff C, Tan W-H, Heimer G, Melmed R, Visootsak J, et al. STARS: results from a safety and efficacy study of OV101 (gaboxadol) in adults and adolescents with Angelman syndrome. In Emerging Science 004, American Academy of Neurology 71st Annual Meeting, Philadelphia, PA, May 2019.

Download references

Author information



Corresponding author

Correspondence to Christopher J. McDougle.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

McDougle, C.J., Keary, C.J. Sleep and EEG biomarkers as avenues toward new treatment approaches in Angelman syndrome. Neuropsychopharmacol. 45, 238–239 (2020).

Download citation


Quick links